🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesGLP-1 and uric acid reduction — my results so far

GLP-1 and uric acid reduction — my results so far

tampaLisa73 Tue, Dec 9, 2025 at 2:00 PM 11 replies 1,054 viewsPage 1 of 3
This thread is more than 6 months old. Information may be outdated. Consider searching for more recent discussions.
tampaLisa73
Member
312
1,456
Oct 2024
Tampa, FL
Dec 9, 2025 at 2:00 PM#1

Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.

The narrow version of the question is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

Tell me what I have not thought of.

6 1RunnerRach, TrialNerd_Beth, HPLC_Greg and 3 others
Reply Quote Save Share Report
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Dec 9, 2025 at 3:50 PM#2
tampaLisa73 said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.7 (insulin resistant) → Current = 1.5 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

5 0PharmD_Rodriguez, julia.endo, JessicaM_2024 and 2 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Dec 9, 2025 at 5:40 PM#3
BenResearch_OR said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 24 → 14 → 7 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

4 24SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 1 other
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Dec 9, 2025 at 7:30 PM#4
tampaLisa73 said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Mine went the same way, slower. Posting only so the count is not one.

Last edited: Dec 9, 2025 at 11:30 PM
3 23FranDenver, Dr.BariatricHTX, LindaRN_retired
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Dec 10, 2025 at 6:19 AM#5

From the other side of the consultation, briefly.

My labs after 6 months on glycaemic control: A1C 5.7%, fasting glucose 92 mg/dL, fasting insulin 5 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.9% and fasting glucose was 117 mg/dL. The improvement has been dramatic and consistent.

2 22claudia_zurich, nancy_portland
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register